Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

Next Previous
X
Search
Trial Profile

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprocitentan (Primary)
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PRECISION
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

    • Most Recent Events

    • 01 Jul 2024 According to an Idorsia Pharmaceuticals Media Release, European Commission (EC) has approved JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. Company will now work to expand marketing authorization by also applying for JERAYGO approval in the UK, Canada, and Switzerland.
    • 03 Jun 2024 Results assessing the % of subjects with controlled blood pressure according to hypertension guidelines at different timepoints during the study, presented at the 33rd European meeting on hypertension and cardiovascular protection.
    • 31 May 2024 According to an Idorsia Pharmaceuticals Media Release, data from the Phase 3 study of aprocitentan will be presented by Prof. Krzysztof Narkiewicz, MD, PhD, at the European Society of Hypertension's 33rd European Meeting of Hypertension and Cardiovascular Protection, taking place in Berlin, Germany, May 31 -June 3, 2024..
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top